Consensus Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
92.85 USD +0.58% Intraday chart for Edwards Lifesciences Corporation +2.22% +21.77%

Evolution of the average Target Price on Edwards Lifesciences Corporation

Price target over the last 5 years

History of analyst recommendation changes

4cc9.g5xhonts7ODuxwp8MJ6K6cN2URrjJoCqiIMCwJdkhP0.zN031i4ptJK5mFUOUe7SpY4DaV2ZUMOc4etOjKMmsbva2hXLHDSmooyAQw~fd77cdb394cb098b8915f6b39d01aa21
Oppenheimer Raises Edwards Lifesciences Price Target to $100 From $93, Maintains Outperform Rating MT
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $97 MT
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating MT
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $86 From $81, Maintains Hold Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Edwards Lifesciences Price Target to $93 From $90, Maintains Outperform Rating MT
Jefferies Adjusts Price Target on Edwards Lifesciences to $102 From $90, Keeps Buy Rating MT
Mizuho Adjusts Price Target on Edwards Lifesciences to $95 From $85, Keeps Buy Rating MT
Baird Adjusts Price Target on Edwards Lifesciences to $100 From $85, Keeps Outperform Rating MT
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $84, Keeps Overweight Rating MT
Truist Adjusts Price Target on Edwards Lifesciences to $97 From $84, Keeps Buy Rating MT
Stifel Adjusts Price Target on Edwards Lifesciences to $83 From $70, Keeps Hold Rating MT
RBC Raises Price Target on Edwards Lifesciences to $95 From $82, Keeps Outperform Rating MT
Morgan Stanley Boosts PT on Edwards Lifesciences to $95 From $80, Notes 'Encouraging' Outlook; Keeps Overweight Rating MT
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile... Our Logo
Futures subdued with focus on pharma earnings, rate expectations RE
MORNING BID AMERICAS-Rates rebound cools, China commands rally RE
Wells Fargo Upgrades Edwards Lifesciences to Overweight From Equal-Weight MT
UBS Adjusts Edwards Lifesciences Price Target to $84 From $79, Maintains Neutral Rating MT
RBC Lifts Price Target on Edwards Lifesciences to $82 From $80, Keeps Outperform Rating MT
Evercore ISI Downgrades Edwards Lifesciences to In Line From Outperform, Adjusts PT to $77 From $80 MT
Truist Securities Adjusts Price Target on Edwards Lifesciences to $78 From $76, Maintains Buy Rating MT
Citigroup Downgrades Edwards Lifesciences to Neutral From Buy, Cuts Price Target to $77 From $85 MT
Morgan Stanley Cuts Price Target on Edwards Lifesciences to $80 From $102, Maintains Overweight Rating MT
RBC Trims Price Target on Edwards Lifesciences to $80 From $82 Ahead of Investor Day, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
92.85 USD
Average target price
91.82 USD
Spread / Average Target
-1.10%
High Price Target
105 USD
Spread / Highest target
+13.09%
Low Price Target
72 USD
Spread / Lowest Target
-22.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Edwards Lifesciences Corporation

BofA Securities
UBS
Canaccord Genuity
Oppenheimer
Jefferies & Co.
Mizuho Securities
Baird
JPMorgan Chase
Truist Securities
RBC Capital Markets
Stifel Nicolaus
Morgan Stanley
Wells Fargo Securities
Evercore ISI
Citigroup
Wolfe Research
Deutsche Bank Securities
TD Cowen
Piper Sandler
Barclays
Bernstein
Raymond James
Goldman Sachs
Cowen
SVB Leerink
Credit Suisse
Atlantic Equities
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
  1. Stock
  2. Equities
  3. Stock Edwards Lifesciences Corporation - Nyse
  4. Consensus Edwards Lifesciences Corporation